BVT Call 45 BMY 21.06.2024/ DE000VD45GM2 /
6/12/2024 9:00:07 AM | Chg.+0.007 | Bid10:00:35 PM | Ask10:00:35 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.017EUR | +70.00% | - Bid Size: - |
- Ask Size: - |
Bristol Myers Squibb... | 45.00 USD | 6/21/2024 | Call |
GlobeNewswire
6/11
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
6/11
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
GlobeNewswire
6/10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
5/31
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire
5/30
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
5/23
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
5/23
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
5/14
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire
5/14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
5/8
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/2
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., ...